Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy

被引:31
|
作者
Diepeveen, SHA
Verhoeven, GHWE
van der Palen, J
Dikkeschei, BLD
van Tits, LJ
Kolsters, G
Offerman, JJG
Bilo, HJG
Stalenhoef, AFH
机构
[1] Univ Med Ctr Nijmegen, Dept Nephrol 545, NL-6500 HB Nijmegen, Netherlands
[2] Isala Clin, Dept Internal Med, Zwolle, Netherlands
[3] Isala Clin, Dept Clin Chem, Zwolle, Netherlands
[4] Med Spectrum Twente, Dept Epidemiol, Enschede, Netherlands
[5] Univ Med Ctr Nijmegen, Dept Gen Internal Med, NL-6500 HB Nijmegen, Netherlands
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 98卷 / 01期
关键词
end-stage renal disease; lipid peroxides; lag time of in vitro LDL oxidation; oxidized LDL; oxidative stress;
D O I
10.1159/000079921
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: In patients with end-stage renal disease (ESRD), cardiovascular complications are the main cause of death. Increased oxidative stress is one of the risk factors for enhanced atherosclerosis in this population. Literature data vary partially dependent on differences in methodology. The present study compares three different methods: plasma lipid peroxides, the newly developed measurement of circulating oxidized LDL(Ox-LDL) particles and the frequently used copper-induced LDL oxidation lag time. Methods: We assessed plasma lipid peroxides, circulating Ox-LDL and in vitro copper-induced LDL oxidation lag time in 47 non-diabetic patients with ESRD, at the start of renal replacement therapy, and compared these with 41 age- and sex-matched controls. Results: In ESRD, total cholesterol (4.6 +/- 1.1 vs. 5.6 +/- 0.9 mmol/l; p < 0.001), LDL cholesterol (2.8 +/- 0.8 vs. 3.5 +/- 0.7 mmol/l; p < 0.001) and HDL cholesterol (1.0 +/- 0.3 vs. 1.4 +/- 0.4 mmol/l; p < 0.001) were lower compared to controls. Plasma lipid peroxides were higher (1.1 +/- 0.5 vs. 0.8 +/- 0.5 mu mol/l; p = 0.003) in ESRD. No differences were observed in plasma Ox-LDL (63.1 +/- 62.0 vs. 55.3 +/- 48.0 mg/l). However, due to the lower plasma LDL cholesterol in ESRD, LDL oxidation level was increased in ESRD (7.1 +/- 0.1 vs. 4.2 +/- 0.3%; p = 0.03). LDL lag time was slightly longer (89 +/- 11 vs. 84 +/- 11 min; p = 0.04) in ESRD. There were no significant differences regarding the amount and rate of dienes produced. Conclusions: Elevated levels of lipid peroxides and higher LDL oxidation levels support the theory that ESRD is associated with increased oxidative stress, which may explain the accelerated atherosclerosis. The measured amount of oxidative stress is not reflected by in vitro oxidizability of LDL. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C3 / C7
页数:5
相关论文
共 50 条
  • [1] Renal replacement therapy in patients with diabetes and end-stage renal disease
    Locatelli, F
    Pozzoni, P
    Del Vecchio, L
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (01): : S25 - S29
  • [2] Management of patients with end-stage renal disease prior to initiation of renal replacement therapy in 2013 in France
    Tuppin, Philippe
    Cuerq, Anne
    Torre, Sylvie
    Couchoud, Cecile
    Fagot-Campagna, Anne
    [J]. NEPHROLOGIE & THERAPEUTIQUE, 2017, 13 (02): : 76 - 86
  • [3] Renal Replacement Therapy in Geriatric End-Stage Renal Disease Patients: A Clinical Approach
    Kooman, Jeroen P.
    Cornelis, Tom
    van der Sande, Frank M.
    Leunissen, Karel M. L.
    [J]. BLOOD PURIFICATION, 2012, 33 (1-3) : 171 - 176
  • [4] Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy
    Isberner, Nora
    Van Daele, Ruth
    Klinker, Hartwig
    Kraus, Sabrina
    Aghai, Fatemeh
    De Vlieger, Greet
    Kuypers, Dirk
    Debaveye, Yves
    Spriet, Isabel
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (12) : 3322 - 3325
  • [5] EFFECT OF RENAL REPLACEMENT THERAPY ON VISCOSITY IN END-STAGE RENAL-DISEASE PATIENTS
    FERIANI, M
    KIMMEL, PL
    KURANTSINMILLS, J
    BOSCH, JP
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (02) : 131 - 139
  • [6] Global variation in renal replacement therapy for end-stage renal disease
    Caskey, Fergus J.
    Kramer, Anneke
    Elliott, Robert F.
    Stel, Vianda S.
    Covic, Adrian
    Cusumano, Ana
    Geue, Claudia
    MacLeod, Alison M.
    Zwinderman, Aeilko H.
    Stengel, Benedicte
    Jager, Kitty J.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (08) : 2604 - 2610
  • [7] Renal replacement therapy in Latin American end-stage renal disease
    Rosa-Diez, Guillermo
    Gonzalez-Bedat, Maria
    Pecoits-Filho, Roberto
    Marinovich, Sergio
    Fernandez, Sdenka
    Lugon, Jocemir
    Poblete-Badal, Hugo
    Elgueta-Miranda, Susana
    Gomez, Rafael
    Cerdas-Calderon, Manuel
    Almaguer-Lopez, Miguel
    Freire, Nelly
    Leiva-Merino, Ricardo
    Rodriguez, Gaspar
    Luna-Guerra, Jorge
    Bochicchio, Tomasso
    Garcia-Garcia, Guillermo
    Cano, Nuria
    Iron, Norman
    Cuero, Cesar
    Cuevas, Dario
    Tapia, Carlos
    Cangiano, Jose
    Rodriguez, Sandra
    Gonzalez, Haydee
    Duro-Garcia, Valter
    [J]. CLINICAL KIDNEY JOURNAL, 2014, 7 (04): : 431 - 436
  • [8] Testosterone metabolism and replacement therapy in patients with end-stage renal disease
    Johansen, KL
    [J]. SEMINARS IN DIALYSIS, 2004, 17 (03) : 202 - 208
  • [9] Enzyme replacement therapy in patients with Fabry disease and end-stage renal disease
    [J]. Nature Clinical Practice Nephrology, 2007, 3 (10): : 525 - 526
  • [10] Renal replacement treatment for end-stage renal disease
    Canaud, B
    Ryckelynck, JP
    Hourmant, MY
    [J]. PRESSE MEDICALE, 2005, 34 (16): : 1197 - 1199